Smartlab Europe

News

Aizon Lauded by Frost & Sullivan for Its AI-powered Platform that Enables Pharma Companies to Achieve Smart and Continuous Manufacturing

Based on its recent analysis of the North American artificial intelligence (AI) market for productivity and compliance in pharmaceuticals, Frost & Sullivan recognizes Aizon with the 2020 North American Enabling Technology Leadership Award. Aizon's good practice (GxP)-compliant, cloud-based, and...

CluePoints Opens New AsiaPac Office in Tokyo

CluePoints, the premier provider of Central Statistical Monitoring, Risk-Based Quality Management and Data Quality Oversight Software for clinical trials, announced further expansion in Japan with the opening of a new office in Tokyo. Dedicated to serving their Japanese clients,...

Piramal Pharma Solutions invests US$ 32 mn to expand Michigan facility

Piramal Pharma Limited’s pharma solutions business, a leading contract development and manufacturing organization (CDMO), is investing US$ 32 million to expand its facility in Michigan with additional capacity and new capabilities for the development and manufacturing of active pharmaceutical...

U.S. FDA confirms Pfizer COVID vaccine safe & effective

The FDA 53-page briefing document gives a green signal to Pfizer-BioNTech COVID-19 vaccine. A US roll-out of the vaccine is expected post-approval from an outside panel of scientific advisers who will review the FDA report on Thursday. As COVID cases...

UK Begins The Biggest Immunization Program In Its History

The UK has begun immunizing citizens against Coronavirus. Population above 80, the most vulnerable and the front line health care workers to be administered with the Pfizer COVID-19 vaccine in the first phase. There is a history in the...

Russia Begins Sputnik V Coronavirus Vaccine Distribution

Sputnik V has been rolled out in Moscow and will be subsequently distributed across other Russian cities. One needs to see if this will halt the growing number of COVID-19 cases in the country. Sputnik V to be...

KaliVir Immunotherapeutics, Astellas ink research agreement to develop and commercialise VET2-L2 novel oncolytic virus

KaliVir Immunotherapeutics LLC and Astellas Pharma Inc announced that they entered into a worldwide licensing agreement for the research, development, and commercialization of VET2-L2, an intravenously administered oncolytic virus for Immuno-Oncology, as well as a research collaboration to generate...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »